SBI-581 is an orally active and potent selective serine-threonine kinase TAO3 inhibitor, with an IC₅₀ of 42 nM. SBI-581 promotes TKS5α accumulation at RAB11-positive vesicles. SBI-581 inhibits invadopodia formation. SBI-581 shows reasonable pharmacokinetics in mice using IP injection. SBI-581 shows antitumor activity^[1].

IC₅₀: 42 nM (TAO3), 237 nM (MEKK3)^[1]

SBI-581 shows moderate selectivity (> 5-10x) against the majority of a broad panel of kinases^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

SBI-581 (10 mg/kg, IP, once) displays reasonable pharmacokinetics (t_1/2=1.5 hr; AUC= 1202 hr*ng/mL; Cmax= ~2 μM)^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

383.44

C₂₄H₂₁N₃O₂

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Iizuka S, et al. Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth. Cancer Res. 2021 Mar 15;81(6):1472-1485.